Navigation Links
Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
Date:9/23/2008

OSLO, September 23 /PRNewswire/ -- Affitech AS, the Norwegian human antibody therapeutics company, today announced that it has accomplished the second milestone in its research and licensing collaboration with Roche to produce fully human recombinant antibodies against an unnamed oncology target. Affitech has successfully used its MBAS (Molecule Based Antibody Screening) system that included its proprietary antibody library and high throughput screening technology to identify several fully human lead antibody candidates. These were then subjected to further engineering in order to generate final candidates that met Roche's various predetermined success criteria. This accomplishment triggered a milestone payment of an undisclosed amount from Roche to Affitech.

"This was a particularly challenging target that Roche asked us to investigate and we are delighted to have delivered a selected group of antibodies, on schedule, that meet their exacting criteria," commented Martin Welschof, Ph.D., Chief Executive Officer of Affitech.

Affitech and Roche entered into this collaboration in 2007 for Affitech to identify and engineer fully human recombinant antibodies against one of Roche's oncology targets. Under the terms of the agreement Roche will now utilize these antibodies for further preclinical evaluation with exclusive rights to develop and commercialize resulting antibodies. Affitech would receive additional milestone payments upon successful development by Roche of these antibodies in oncology or other indications and royalties on worldwide net sales of any successfully developed product candidates.

Notes to Editors:

About Affitech

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company's proprietary product candidates currently in development were generated by CBAS(TM). Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as Omeros, Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Further information at http://www.affitech.com.

Contacts for Affitech:

Affitech (Norway):

Dr. Martin Welschof

Chief Executive Officer

+47-22-95-87-58

m.welschof@affitech.com

Affitech (USA):

Dr. Rathin C. Das President

+1-925-935-9803

r.das@affitech.com


'/>"/>
SOURCE Affitech AS
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech Appoints Dr. Keith McCullagh as Chairman
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
5. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
6. BioElectronics Corp. Announces $400,000 in New Orders From the Middle East
7. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
8. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
9. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
10. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
11. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... , ... July 15, 2019 , ... CRISPR is often ... a certain trait can be removed, replaced, or edited, but Yiping Qi, assistant professor ... beyond these traditional applications in his latest publication in Nature Plants. In this comprehensive ...
(Date:7/9/2019)... ... ... Today, at the BIO World Congress on Industrial Biotechnology and ... the winners of the Consider Corn Challenge II. Three winners were chosen, each with ... biobased materials. , “Corn is a sustainable, abundant and affordable industrial feedstock ...
(Date:6/18/2019)... (PRWEB) , ... June 17, 2019 , ... ... that they have entered into an agreement for production and manufacturing of GMP-grade ... the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the ...
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements with Ted Danson ... scheduled to broadcast 4Q/2019. Check your local listings for more information. , Advancements ... how its technology facilitates laboratories to improve efficiency and quality of research by ...
Breaking Biology Technology:
(Date:6/20/2019)... , ... June 19, 2019 , ... ... by the Infectious Diseases Society of America Foundation, and the possibly millions of ... to study infectious agents in AD, are a “welcome affirmation” of the need ...
(Date:6/16/2019)... , ... June 14, 2019 , ... ... invited to lecture at the fifth annual Neodent World Congress. Attended by thousands ... innovative progress and latest advancements in the world of dentistry. The three-day event ...
(Date:6/13/2019)... ... , ... KICVentures announced today its plans to host an event ... ASC Conference in Chicago on Thursday, June 13th at 6:30 pm. The event will ... the 3rd floor Ticino Hospitality room in space #74T. , The event will feature ...
Breaking Biology News(10 mins):